- Home
- BIIB vs EVRG Comparison
BIIB vs EVRG Comparison
Compare BIIB & EVRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- EVRG
- Stock Information
- Founded
- BIIB 1978
- EVRG 2017
- Country
- BIIB United States
- EVRG United States
- Employees
- BIIB N/A
- EVRG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- EVRG Power Generation
- Sector
- BIIB Health Care
- EVRG Utilities
- Exchange
- BIIB Nasdaq
- EVRG Nasdaq
- Market Cap
- BIIB 18.7B
- EVRG 17.9B
- IPO Year
- BIIB 1991
- EVRG N/A
- Fundamental
- Price
- BIIB $155.64
- EVRG $76.53
- Analyst Decision
- BIIB Buy
- EVRG Strong Buy
- Analyst Count
- BIIB 24
- EVRG 10
- Target Price
- BIIB $174.62
- EVRG $77.35
- AVG Volume (30 Days)
- BIIB 1.6M
- EVRG 2.2M
- Earning Date
- BIIB 10-30-2025
- EVRG 11-06-2025
- Dividend Yield
- BIIB N/A
- EVRG 3.63%
- EPS Growth
- BIIB N/A
- EVRG N/A
- EPS
- BIIB 10.97
- EVRG 3.66
- Revenue
- BIIB $10,065,900,000.00
- EVRG $5,878,800,000.00
- Revenue This Year
- BIIB $2.97
- EVRG $5.19
- Revenue Next Year
- BIIB N/A
- EVRG $3.76
- P/E Ratio
- BIIB $14.24
- EVRG $20.94
- Revenue Growth
- BIIB 4.77
- EVRG 1.75
- 52 Week Low
- BIIB $110.04
- EVRG $59.67
- 52 Week High
- BIIB $175.86
- EVRG $79.32
- Technical
- Relative Strength Index (RSI)
- BIIB 62.21
- EVRG 49.30
- Support Level
- BIIB $151.83
- EVRG $74.76
- Resistance Level
- BIIB $157.79
- EVRG $77.36
- Average True Range (ATR)
- BIIB 4.71
- EVRG 1.23
- MACD
- BIIB 0.51
- EVRG -0.38
- Stochastic Oscillator
- BIIB 91.06
- EVRG 41.67
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.